
Trestle Biotherapeutics
Trestle Biotherapeutics is a YC Winter 2021 (W21) company. Based in San Diego, CA, USA. Team of 2.
About Trestle Biotherapeutics
Summary
Trestle Biotherapeutics develops implantable, bioengineered renal tissue for patients with end-stage renal disease. The tissue supplements remaining kidney function after surgical delivery, reducing or eliminating the patient's dependence on dialysis and extending the window before a full kidney transplant becomes necessary. It targets a condition where the only current options are dialysis or a scarce donor organ.
Go-to-market
The therapy targets end-stage renal disease patients who would otherwise require dialysis or a kidney transplant, delivered through a surgical implantation procedure in a clinical setting.
From the Y Combinator listing
Bioengineered kidneys for patients with kidney failure
We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.
Facts
- Healthcare / Healthcare -> Industrial Bio
- San Diego, CA, USA
- 2
- Active
- Early
Founders (2)
- Alice Chen
- Ben Shepherd
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works